Phase III Study of ASP7374 Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects

Trial Profile

Phase III Study of ASP7374 Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Jan 2017 According to an Astellas Pharma media release, the company will withdraw the application for marketing approval of ASP7374 which the company has filled in Japan as the company has terminated the development agreement with UMN Pharma.
    • 11 Mar 2013 Results have been reported in an Astellas Pharma media release.
    • 18 Jan 2013 New source identified and integrated (ClinicalTrials.gov record NCT01767896).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top